The effect of cholinergic basal forebrain lesions on immunoreactivity to somatostatin (SOM-i) and neuropeptide-Y (NPY-i) was investigated in the rat parietal cortex, 16-18 months after multiple bilateral ibotenic acid injections in the nucleus basalis complex, As a result of the lesion, the cholinergic fiber density in the cortex decreased by 66% with a concurrent increase in SOM-i fibers by more than 50% and a 124% increase in NPY-i fiber innervation. The neuropeptidergic sprouting response on cholinergic denervation does not match the concurrent cholinergic and peptidergic decline in Alzheimer's disease and as such does not support the cholinergic lesion alone as an animal model for this neurodegenerative disorder.
The systemic breakdown of the magnocellular basal forebrain complex, which is the subcortical source of cholinergic innervation of cortex and hippocampus ~6"]8, is the most consistent transmitterspecific change found in Alzheimer's disease (AD). These findings led to the cholinergic hypothesis for dementia, which assumes a major role of specific cholinergic decline of the basal forebrain system in the causation of the neuropathology found in Alzheimer's disease 2'6 and its characteristic impairment of learning and memory. Ever since, a large number of studies were initiated on experimental cholinergic basal forebrain lesions in search for an animal model for this neurodegenerative disorder j'7'~3'15'2°~22 To validate the cholinergic forebrain lesion as a dementia model, or in general to study complex learningmemory functions of the forebrain, this experimental model should meet several criteria. First, cholinergic forebrain lesions should mimic the persistent amnesic deficits characteristic for the dementia syndromes. Indeed, experimental damage to the magnocellular basal nucleus and the medial septal area under certain conditions results in a permanent deterioration of the performance of animals in a variety of learning and memory tasks 13-15"2°'22. Second, the specific cholinergic forebrain lesion should lead to similar biochemical and anatomical effects in cortex and hippocampus which define the neuropathoiogy in AD. In this respect, several neurotransmitter and neuropeptidergic systems in the cortical mantle appear to be affected 3'4'9. For neuropeptides there is ample evidence that somatostatin (SOM) and neuropeptide Y (NPY) systems in cortex and hippocampus are severely damaged and involved in the formation of neurofibrillary tangles and neuritic plaques 3~4"~. In the present investigation we aimed at assessing whether the concurrent cholinergic and peptidergic decline in AD are causally related or independent degenerative phenomena. In the currently used experimental design the cholinergic lesion and prolonged cortical cholinergic denervation was obtained by multiple injections in the magnocellular basal forebrain complex (MBN) with the excitotoxin ibotenic acid, followed by extended survival periods of 16-18 months. In our view such long-term effects of cholinergic lesions into the aging stage of the experimental animal bear more resemblance to the human neuropathology. From recent
